Cambridge Investment Research Advisors Inc. Has $2.03 Million Holdings in Baxter International Inc (NYSE:BAX)

Cambridge Investment Research Advisors Inc. reduced its position in Baxter International Inc (NYSE:BAX) by 1.1% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 24,219 shares of the medical instruments supplier’s stock after selling 271 shares during the period. Cambridge Investment Research Advisors Inc.’s holdings in Baxter International were worth $2,025,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of the business. BlackRock Inc. increased its position in Baxter International by 1.4% in the 2nd quarter. BlackRock Inc. now owns 40,589,288 shares of the medical instruments supplier’s stock worth $3,324,263,000 after purchasing an additional 560,814 shares during the last quarter. State Street Corp increased its holdings in shares of Baxter International by 2.6% during the 3rd quarter. State Street Corp now owns 24,189,517 shares of the medical instruments supplier’s stock valued at $2,120,911,000 after acquiring an additional 620,579 shares during the last quarter. California Public Employees Retirement System increased its holdings in shares of Baxter International by 3.6% during the 3rd quarter. California Public Employees Retirement System now owns 3,792,899 shares of the medical instruments supplier’s stock valued at $331,765,000 after acquiring an additional 132,885 shares during the last quarter. Parametric Portfolio Associates LLC increased its holdings in shares of Baxter International by 2.0% during the 3rd quarter. Parametric Portfolio Associates LLC now owns 1,834,699 shares of the medical instruments supplier’s stock valued at $160,481,000 after acquiring an additional 36,166 shares during the last quarter. Finally, Haverford Trust Co. increased its holdings in shares of Baxter International by 0.6% during the 3rd quarter. Haverford Trust Co. now owns 1,127,952 shares of the medical instruments supplier’s stock valued at $98,662,000 after acquiring an additional 6,974 shares during the last quarter. 82.61% of the stock is currently owned by institutional investors.

In related news, Director John D. Forsyth sold 1,500 shares of the stock in a transaction that occurred on Friday, December 13th. The stock was sold at an average price of $83.64, for a total transaction of $125,460.00. Following the completion of the sale, the director now owns 30,078 shares in the company, valued at approximately $2,515,723.92. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 0.70% of the stock is owned by corporate insiders.

A number of research analysts have recently commented on the company. Citigroup raised Baxter International from a “neutral” rating to a “buy” rating in a report on Thursday, January 2nd. Wells Fargo & Co increased their price objective on Baxter International from $100.00 to $102.00 and gave the company an “overweight” rating in a report on Friday. Cfra increased their price objective on Baxter International from $87.00 to $93.00 and gave the company a “hold” rating in a report on Thursday, February 6th. JPMorgan Chase & Co. increased their price objective on Baxter International from $89.00 to $94.00 and gave the company an “overweight” rating in a report on Friday, December 20th. Finally, UBS Group reissued a “buy” rating and set a $102.00 price objective on shares of Baxter International in a report on Monday, January 13th. Six investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $93.50.

Shares of NYSE:BAX opened at $93.14 on Friday. The business has a 50 day moving average price of $88.60 and a 200 day moving average price of $85.45. Baxter International Inc has a twelve month low of $72.42 and a twelve month high of $95.00. The company has a market cap of $47.26 billion, a price-to-earnings ratio of 28.66, a PEG ratio of 2.16 and a beta of 0.96. The company has a quick ratio of 2.10, a current ratio of 2.78 and a debt-to-equity ratio of 0.72.

About Baxter International

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies.

Recommended Story: 52-Week High/Low Prices For Stock Selection

Want to see what other hedge funds are holding BAX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Baxter International Inc (NYSE:BAX).

Institutional Ownership by Quarter for Baxter International (NYSE:BAX)

Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.